Responses
Inflammatory arthritis
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Compose a Response to This Article
Other responses
No responses have been published for this article.